JCA-Mauvernay Award

Launched in 2005 by the Japanese Cancer Association and Debiopharm Group

The JCA-Mauvernay Award is organized each year in collaboration with the Japanese Cancer Association (JCA). This award has a total value of CHF 25’000 and it aims at recognizing outstanding achievements in the field of oncology amongst Japanese researchers, in both the fundamental and the clinical aspects.

In 2014, the JCA-Mauvernay Award celebrated its 10th anniversary (watch the video here).

Enso illustration:Like the open Ensō, research in oncology is never complete, it is a never-ending process

Press Releases

September 26, 2023

Debiopharm Recognizes Pioneering Japanese Cancer Research During The 82nd JCA-Mauvernay Award Ceremony

Read more
October 3, 2022

Debiopharm reinforces the bond between Swiss and Japanese cancer research with the 2022 JCA-Mauvernay Award Ceremony

Read more
October 4, 2021

Debiopharm Encourages Breakthough Cancer Research In Japan Through its Competitive JCA Mauvernay Award

Read more

All Press Releases